Hospital activity before and after diagnosis of monoclonal gammopathy of undetermined significance (MGUS)

Maxine Lamb; Eleanor Victoria Kane; Alexandra Gwen Smith; Eve Roman

doi:10.1038/s41416-019-0555-x

Hospital activity before and after diagnosis of monoclonal gammopathy of undetermined significance (MGUS)

Maxine Lamb, Eleanor Victoria Kane, Alexandra Gwen Smith, Eve Roman

Health Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

Monoclonal gammopathy of undetermined significance (MGUS; ICD-O-3=9761/1) is a premalignant clonal disorder that progresses to myeloma at ~1% per year. Whilst MGUS is often diagnosed incidentally and other symptoms of myeloma are absent, several follow-up studies have reported relationships with co-morbidities and poor survival. Illness patterns before MGUS diagnoses have, however, not been examined in relation to those seen after diagnosis. Here we compare hospital activity of people with MGUS and patients with mature B-cell malignancies to that in the general population.

Original language	English
Article number	37
Journal	British journal of cancer
Volume	121
Early online date	4 Oct 2019
DOIs	https://doi.org/10.1038/s41416-019-0555-x
Publication status	Published - 28 Oct 2019
Event	The National Cancer Research Institute (NCRI) Cancer Conference 2019 - Glasgow, United Kingdom Duration: 3 Nov 2019 → 5 Nov 2019

Bibliographical note

If any changes are made to this PURE entry can you please inform [email protected]
Selected Abstracts from the 2019 NCRI Cancer Conference of National Cancer Research Institute

Access to Document

10.1038/s41416-019-0555-x

Cite this

@article{265af186cb214b1ead14a1928ae8906c,

title = "Hospital activity before and after diagnosis of monoclonal gammopathy of undetermined significance (MGUS)",

abstract = "Monoclonal gammopathy of undetermined significance (MGUS; ICD-O-3=9761/1) is a premalignant clonal disorder that progresses to myeloma at ~1% per year. Whilst MGUS is often diagnosed incidentally and other symptoms of myeloma are absent, several follow-up studies have reported relationships with co-morbidities and poor survival. Illness patterns before MGUS diagnoses have, however, not been examined in relation to those seen after diagnosis. Here we compare hospital activity of people with MGUS and patients with mature B-cell malignancies to that in the general population.",

author = "Maxine Lamb and Kane, {Eleanor Victoria} and Smith, {Alexandra Gwen} and Eve Roman",

note = "If any changes are made to this PURE entry can you please inform [email protected] Selected Abstracts from the 2019 NCRI Cancer Conference of National Cancer Research Institute; The National Cancer Research Institute (NCRI) Cancer Conference 2019, NCRI 2019 ; Conference date: 03-11-2019 Through 05-11-2019",

year = "2019",

month = oct,

day = "28",

doi = "10.1038/s41416-019-0555-x",

language = "English",

volume = "121",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Hospital activity before and after diagnosis of monoclonal gammopathy of undetermined significance (MGUS)

AU - Lamb, Maxine

AU - Kane, Eleanor Victoria

AU - Smith, Alexandra Gwen

AU - Roman, Eve

N1 - If any changes are made to this PURE entry can you please inform [email protected] Selected Abstracts from the 2019 NCRI Cancer Conference of National Cancer Research Institute

PY - 2019/10/28

Y1 - 2019/10/28

N2 - Monoclonal gammopathy of undetermined significance (MGUS; ICD-O-3=9761/1) is a premalignant clonal disorder that progresses to myeloma at ~1% per year. Whilst MGUS is often diagnosed incidentally and other symptoms of myeloma are absent, several follow-up studies have reported relationships with co-morbidities and poor survival. Illness patterns before MGUS diagnoses have, however, not been examined in relation to those seen after diagnosis. Here we compare hospital activity of people with MGUS and patients with mature B-cell malignancies to that in the general population.

AB - Monoclonal gammopathy of undetermined significance (MGUS; ICD-O-3=9761/1) is a premalignant clonal disorder that progresses to myeloma at ~1% per year. Whilst MGUS is often diagnosed incidentally and other symptoms of myeloma are absent, several follow-up studies have reported relationships with co-morbidities and poor survival. Illness patterns before MGUS diagnoses have, however, not been examined in relation to those seen after diagnosis. Here we compare hospital activity of people with MGUS and patients with mature B-cell malignancies to that in the general population.

UR - http://www.scopus.com/inward/record.url?scp=85073055586&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0555-x

DO - 10.1038/s41416-019-0555-x

M3 - Meeting abstract

C2 - 31591445

SN - 0007-0920

VL - 121

JO - British journal of cancer

JF - British journal of cancer

M1 - 37

T2 - The National Cancer Research Institute (NCRI) Cancer Conference 2019

Y2 - 3 November 2019 through 5 November 2019

ER -

Hospital activity before and after diagnosis of monoclonal gammopathy of undetermined significance (MGUS)

Abstract

Bibliographical note

Access to Document

Other files and links

Cite this